您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > nAChR agonist 1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
nAChR agonist 1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
nAChR agonist 1图片
规格:98%
分子量:419.94
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
nAChR agonist 1 是一种有效的、脑通透性强的、口服有效的 α7 烟碱乙酰胆碱受体 (α7 nicotinic acetylcholine receptor) 的正向变构调节剂。nAChR agonist 1 在 Ca2+ 中,对内源性表达 α7 nAChR 的人 IMR-32 神经母细胞瘤细胞的 EC50 为 0.32 μM。nAChR agonist 1 可用于阿尔茨海默病的研究。
货号:ajcx35008
CAS:1394371-75-5
分子式:C20H18ClNO3S2
分子量:419.94
溶解度:DMSO : 125 mg/mL (297.66 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 µM in a Ca2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease[1].

Acute (single-dose) oral administration of nAChR agonist 1 (compound 28) prior to memory acquisition, significantly increased the discrimination index in both time-delay and scopolamine-induced 8 amnesia at 1 and 3 mg/kg dose levels in male Wistar rats.nAChR agonist 1 also significantly improved the discrimination index in the memory consolidation paradigm, when administered immediately after the memory acquisition trial[1].nAChR agonist 1 treatment (10 mg/kg; p.o.) shows that the AUC, Cmax, and F values are 63 h μM, 2.3 μM, 63%, respectively[1].nAChR agonist 1 (1 mg/kg; i.v.) treatment shows that the AUC, Cmax,T1/2, CL, and Vss are 1.3 h μM, 0.9 μM, 1.4 hours, 31 mL/min/kg, 3 L/kg, respectively[1].

[1]. Sinha N, et al.Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure-Activity Relationship and Preclinical Characterization. J Med Chem. 2020 Feb 13;63(3):944-960.